- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gefapixant effective option for uncontrolled chronic cough, finds study
Gefapixant controls chronic refractory cough by inhibiting P2X3 receptors that are associated with neuronal hypersensitization in the airways and lungs leading to chronic cough.
New Orleans: Gefapixant is an orally administered, selective P2X3 receptor antagonist. It is believed that excessive activation of P2X3 receptors is associated with neuronal hypersensitization in the airways and lungs leading to chronic cough.
Chronic refractory cough (CRC) is defined as a cough that persists despite guideline-based treatment. It is seen in 20-46% of patients presenting to specialist cough clinics and it has a substantial impact on the quality of life and healthcare utilization.
2 ongoing pivotal phase 3 trials (COUGH-1 and COUGH-2) for gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough is conducted which is published in the journal Clinical Trials.
The study is a randomized, double-blind, placebo-controlled that enrolled 732 and 1317 adult patients with refractory or unexplained chronic cough for at least 1 year, respectively. Both studies randomized patients to 1 of 3 cohorts: gefapixant 45mg or 15mg twice daily, or placebo.
Inclusion Criteria were:
• Chest radiograph or computed tomography scan of the thorax (within 5 years of Screening/Visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator
• Has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough
• Is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance
• Provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires)
The primary endpoint was 12-week Awake Objective Cough Frequency, with secondary endpoints including various measures of cough severity and quality of life: the 7-item Cough Severity Diary (CSD), the participant-rated Patient Global Impression of Change (PGIC), and the 19-item Leicester Cough Questionnaire (LCQ).
Improvements in [patient reported outcomes] in this trial are consistent with data on objective cough frequency reductions and indicate benefits related to the quality of life," the researchers concluded.
For further reading click on the following,
MBBS
Dr K B AARTHI-has completed MBBS from SRM UNIVERSITY TAMIL NADU,Her interest is in the field of Pediatrics and Anaesthesia, also passionate in doing research and publishing articles.She joined Medical Dialogues in 2020 and publishes health news and medical updates. Email: editorial@medicaldialogues.in. Contact no. 011-43720751,9786713226
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751